ClinicalTrials.gg
CompletedNCT02724020Updated Nov 19, 2021Results posted

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

A Phase 2 interventional study of Everolimus and MLN0128 in Clear-cell Metastatic Renal Cell Carcinoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 36 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies in Clear-cell metastatic renal cell carcinoma with a site in United States — 17 open to participants now, 22 under way, 3 of them phase 3. Clear-cell metastatic renal cell carcinoma · United States.

Enrollment
11th of 37
96 · median 34
Started
2016
with 1 other
Phase 2
15 of 38
5 open now
Registered
7th of 38
by date

Among the 38 studies in Clear-cell metastatic renal cell carcinoma with a site in United States, this one is the 11th largest by enrollment of the 37 interventional ones that give a count, is one of 2 that started in 2016, is one of 15 in phase 2, and was the 7th registered.

Clear-cell metastatic renal cell carcinoma

70 studies on the registry are indexed under Clear-cell metastatic renal cell carcinoma; 31 are open to participants now.

Browse Clear-cell metastatic renal cell carcinoma studies →

Open to participants now

17 of the 38 studies in Clear-cell metastatic renal cell carcinoma with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Clear-cell metastatic renal cell carcinoma studies recruiting now, 22 (88%) set no upper age limit and 1 (4%) stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Clear-cell metastatic renal cell carcinoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of single-agent MLN0128 and the combination of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with metastatic clear-cell renal cell carcinoma (mccRCC) that have progressed on vascular endothelial growth factor (VEGF)-targeted therapy.

Read the detailed description

The drugs being tested in this study are called MLN0128 and MLN1117. MLN0128 and MLN1117 are being tested to treat people who have mccRCC. This study will assess the efficacy and safety of MLN0128 and MLN1117 as well as how it is processed by the body in participants with advanced or mccRCC.

The study will enroll approximately 96 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups:

  • Everolimus 10 mg once daily
  • MLN0128 30 mg once weekly
  • MLN0128 4 mg once daily for 3 days per week + MLN1117 200 mg once daily for 3 days per week

All participants will be asked to take the study drug at the same time on each scheduled day.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is 2 years after last participant is randomized, or when the last participant discontinues study treatment (approximately 3 years). Participants will make multiple visits to the clinic including a follow-up visit 30 to 40 days after receiving their last dose of study drug or prior to start of subsequent anticancer therapy for safety assessment. Participants will then be followed for Progression Free and Overall Survival.

03

Conditions studied

  • Clear-cell Metastatic Renal Cell Carcinoma

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 18 years or older.
  2. confirmed renal cell carcinoma (RCC) with a clear-cell component.
  3. Evidence that the RCC is advanced or .
  4. Radiologic evidence of PD (according to Version 1.1) either during or within 6 months after stopping their most recent systemic therapy for RCC before enrollment into this study.
  5. At least 1, prior line of VEGF-targeted therapy, but not more than 4 total . Exposure to more than 1 line of VEGF-targeted therapy is acceptable. Participants may also have received prior therapies with interferon, interleukin 2 (IL-2), anti-PD1 antibodies, cabozantinib or other experimental agents, but not prior therapy with any agent that targets phosphoinositide 3-kinase (PI3K), serine/ threonine-specific protein kinase (AKT), or mechanistic (or mammalian) target of rapamycin (mTOR).
  6. Performance Status (KPS) greater than or equal to (>=) 70%.
  7. of >=3 months.
  8. Female participants who:

    • Are for at least 1 year before the screening visit, OR
    • Are surgically sterile, OR
    • If they are of , agree to practice 1 highly effective method of , and 1 additional effective (barrier) method, at the same time, from the time of signing the through 90 days (or longer, as mandated by local labelling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc;]) after the last dose of study drug, OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant. (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.).

    Male participants, even if surgically sterilized (that is, status postvasectomy), who:

    • Agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of study drug (or longer, as mandated by local labelling [example, USPI, SmPC, etc]), OR
    • Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant (Periodic abstinence [example, calendar, ovulation, symptothermal, postovulation methods for the female partner], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception. Female and male condoms should not be used together.).
    • Agree not to donate sperm during the course of this study or within 120 days after receiving their last dose of study drug.
  9. Suitable venous access for the study-required blood sampling.
  10. Screening clinical laboratory values:

    • >=2000 per microliter (/mcL) and count >=100,000/mcL;
    • (ALT) and aspartate aminotransferase (AST) less than or equal to (\<=) 2.5*the (ULN);
    • Total \<=1.5*ULN;
    • Estimated by Cockcroft-Gault >=40 milliliter per minute (mL/min) / 1.73 square meter (m\^2);
    • Glycosylated () less than (\<) 7.0%, fasting serum glucose \<=130 milligram per deciliter (mg/dL), and fasting triglycerides \<=300 mg/dL.
  11. At least 14 days since the end of prior systemic VEGF-targeted treatment (that is, sunitinib, pazopanib, axitinib, or sorafenib), radiotherapy, or surgical procedure with resolution of all treatment-related toxicity (except alopecia and hypothyroidism) either to Grade 0 or 1 (National Cancer Institute [NCI CTCAE] Version 4.03) or to baseline.
  12. At least 21 days since the last dose of bevacizumab, other antibody, or interferon.
  13. Voluntary written consent given before performance of any study-related procedure not part of standard medical care, with the understanding that consent may be withdrawn by the participant at any time without prejudice to future medical care.

Exclusion criteria

Exclusion Criteria:

  1. Central nervous system (CNS) .
  2. Other co-morbidities, such as uncontrolled pulmonary disease, active CNS disease, active infection, or any other condition that might compromise the participant's participation in the study.
  3. Known infection.
  4. Known surface antigen-positive, or known or suspected active infection.
  5. Manifestations of malabsorption due to prior gastrointestinal (GI) surgery, GI disease, or for an unknown reason that may alter the absorption of everolimus, MLN0128, or MLN1117. In addition, participants with enteric stomata are excluded.
  6. Women who are either breast feeding or pregnant.
  7. History of any of the following within the last 6 months before administration of the first dose of study drug

    • Ischemic myocardial event, including angina requiring therapy and artery revascularization procedures;
    • Ischemic cerebrovascular event, including and artery revascularization procedures;
    • Requirement for inotropic support (excluding digoxin), or serious (uncontrolled) cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia);
    • Placement of a pacemaker for control of rhythm;
    • Class III or IV heart failure;
    • Pulmonary embolism.
  8. Significant active cardiovascular or pulmonary disease including:

    • Uncontrolled hypertension (that is, either systolic blood pressure greater than [>] 160 millimeter of mercury [mm Hg]; diastolic blood pressure >95 mm Hg). Use of anti-hypertensive agents to control hypertension before Cycle 1 Day 1 is allowed;
    • Pulmonary hypertension.
    • Uncontrolled asthma or oxygen saturation \<90% by arterial blood gas analysis or pulse oximetry on room air.
    • Significant valvular disease; severe regurgitation or stenosis by imaging independent of symptom control with medical intervention; or history of valve replacement.
    • Medically significant (symptomatic) bradycardia.
    • History of arrhythmia requiring an implantable cardiac defibrillator.
    • Baseline prolongation of the rate- interval (QTc; example, repeated demonstration of QTc interval >480 millisecond [ms], or history of congenital, long-QT syndrome, or torsades de pointes).
  9. Diagnosed or treated for another within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer, superficial bladder cancer, very low risk prostate on observation, or carcinoma in situ of any type are not excluded if they have undergone complete resection.
  10. Prior therapy with agents that target Phosphatidylinositide 3-kinases (PI3K), Protein kinase B (AKT), or mechanistic target of rapamycin (mTOR). Participants with known to everolimus or rapamycin derivatives are also excluded.
  11. Any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
  12. Participants who have taken a proton pump inhibitor (PPI) within 3 days before receiving the first dose of study drug.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Active comparator
    Arm A: Single-agent Everolimus 10 mg QD

    Everolimus 10 mg capsules, orally, once daily in a 28-day treatment cycle until disease progression, consent withdrawal, death, or transfer to the Post-trial Access (PTA) program (Median duration of treatment was 15.43 weeks up to end of study).

    Drug: Everolimus

  • Experimental
    Arm B: Single-agent MLN0128 30 mg QW

    MLN0128 30 mg capsules, orally, once weekly on Days 1, 8, 15, and 22 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.64 weeks up to end of study).

    Drug: MLN0128

  • Experimental
    Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD

    MLN0128 4 mg and MLN1117 200 mg capsules, orally, both once daily for 3 days per week (QD X 3) on Days 1-3, 8-10, 15-17, and 22-24 of a 28-day treatment cycle until disease progression, unacceptable toxicity, consent withdrawal, death, or transfer to the PTA program (Median duration of treatment was 9.43 weeks up to end of study).

    Drug: MLN0128 · Drug: MLN1117

Interventions

  • Everolimus capsules.

  • MLN0128 capsules.

    Also known as: TAK-228, INK0128

  • MLN1117 capsules.

    Also known as: TAK-117, INK1117

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: From first dose of study drug up to disease progression or death, assessed up to 43 months

Secondary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in participants administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. TEAE was defined as the event that occur after administration of the first dose of study drug and through 30 days after the last dose of study drug.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (approximately up to 31 months)

  2. Overall Survival (OS)

    Overall survival in months was defined as the time from the date of randomization to the date of death.

    Time frame: From first dose of study drug through 30 days after the last dose of study drug (up to 51 months)

  3. Time-to-progression (TTP)

    TTP in months is defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

    Time frame: From first dose of study drug up to disease progression or death (up to 51 months)

  4. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants among response evaluable analysis set who achieve a best overall response of complete response (CR) or partial response (PR) based on investigators assessment of response following RECIST 1.1. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

    Time frame: From first dose of study drug to disease progression or death (up to 51 months)

  5. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of participants who achieve a best response of CR, PR or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: From first dose of study drug up to disease progression or death (up to 51 months)

  6. CBR With SD Duration of at Least 16 Weeks

    CBR with SD duration of at least 4 months (CBR-16) was defined as the percentage of participants who achieve CR or PR of any duration or have SD with duration of at least 16 weeks. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Up to Week 16

07

Results

Posted Feb 21, 2021

Participant flow

Participants took part in the study at approximately 60-70 investigative sites in Czech Republic, France, Italy, Poland, Spain, United Kingdom, Canada and United States from 30 June 2016 to 13 October 2020.

Participant flow — Overall Study
MilestoneArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Started323232
Treated (safety analysis set)323231
Completed000
Not completed323232
Withdrew: Death161819
Withdrew: Lost to follow-up030
Withdrew: Site terminated by sponsor1588
Withdrew: Withdrawal by subject135

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
From first dose of study drug up to disease progression or death, assessed up to 43 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Progression-Free Survival (PFS)3.8 (2.0 to 5.4)3.6 (1.9 to 5.7)3.1 (1.9 to 5.4)
Statistical analysis
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm B: Single-agent MLN0128 30 mg QW · Stratified Log-rank Test · p = =0.388 · Hazard ratio (hr): 1.33 · 95% CI 0.75 to 2.36HR obtained by stratified Cox proportion hazard model adjusted for prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category. A hazard ratio \< 1 indicated an advantage compared to Everolimus.
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD · Stratified Log-rank Test · p = 0.667 · Hazard ratio (hr): 1.37 · 95% CI 0.75 to 2.52HR obtained by stratified Cox proportion hazard model adjusted for prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category. A hazard ratio \< 1 indicated an advantage compared to Everolimus.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in participants administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product. TEAE was defined as the event that occur after administration of the first dose of study drug and through 30 days after the last dose of study drug.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (approximately up to 31 months)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)323031
SecondaryOverall Survival (OS)

Overall survival in months was defined as the time from the date of randomization to the date of death.

Time frame:
From first dose of study drug through 30 days after the last dose of study drug (up to 51 months)
Reported as:
Median · months
Overall Survival (OS)
monthsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Overall Survival (OS)22.4 (8.2 to NA)16.2 (9.0 to 19.9)18.1 (6.2 to 23.4)
Statistical analysis
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm B: Single-agent MLN0128 30 mg QW · Stratified Log-rank Test · p = 0.212 · Hazard ratio (hr): 1.76 · 95% CI 0.89 to 3.49HR obtained by stratified Cox proportion hazard model adjusted for prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category. A hazard ratio \< 1 indicated an advantage compared to Everolimus.
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD · Stratified Log-rank Test · p = 0.546 · Hazard ratio (hr): 1.51 · 95% CI 0.77 to 2.98HR obtained by stratified Cox proportion hazard model adjusted for prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category. A hazard ratio \< 1 indicated an advantage compared to Everolimus.
SecondaryTime-to-progression (TTP)

TTP in months is defined as the time from the date of randomization to the date of first documentation of progression. Per RECIST v1.1, PD was defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Time frame:
From first dose of study drug up to disease progression or death (up to 51 months)
Reported as:
Median · months
Time-to-progression (TTP)
monthsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Time-to-progression (TTP)3.8 (2.0 to 15.6)3.5 (1.9 to 7.4)3.7 (1.9 to 10.5)
Statistical analysis
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm B: Single-agent MLN0128 30 mg QW · Log Rank · p = =0.156 · Hazard ratio (hr): 1.57 · 95% CI 0.81 to 3.05HR obtained by stratified Cox proportion hazard model adjusted for prior lines of therapy and the International Metastatic Renal Cell Carcinoma Database Consortium risk category. A hazard ratio \< 1 indicates an advantage compared to Everolimus.
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD · Log Rank · p = 0.667 · Hazard ratio (hr): 1.42 · 95% CI 0.72 to 2.79HR obtained by stratified Cox proportion hazard model adjusted for prior lines of therapy and the International Metastatic Renal Cell Carcinoma Database Consortium risk category. A hazard ratio \< 1 indicates an advantage compared to Everolimus.
SecondaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants among response evaluable analysis set who achieve a best overall response of complete response (CR) or partial response (PR) based on investigators assessment of response following RECIST 1.1. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.

Time frame:
From first dose of study drug to disease progression or death (up to 51 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Objective Response Rate (ORR)15.606.5
Statistical analysis
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD · Odds ratio (or): 0.41 · 95% CI 0.08 to 2.22Odds ratio and 95% CI were obtained using a stratified CMH model with prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category.
SecondaryClinical Benefit Rate (CBR)

CBR is defined as the percentage of participants who achieve a best response of CR, PR or stable disease (SD) of any duration. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
From first dose of study drug up to disease progression or death (up to 51 months)
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
Clinical Benefit Rate (CBR)62.550.054.8
Statistical analysis
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm B: Single-agent MLN0128 30 mg QW · Odds ratio (or): 0.64 · 95% CI 0.24 to 1.69Odds ratio and 95% CI was obtained using a stratified CMH model with prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category.
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD · Odds ratio (or): 0.79 · 95% CI 0.28 to 2.21Odds ratio and 95% CI was obtained using a stratified CMH model with prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category.
SecondaryCBR With SD Duration of at Least 16 Weeks

CBR with SD duration of at least 4 months (CBR-16) was defined as the percentage of participants who achieve CR or PR of any duration or have SD with duration of at least 16 weeks. CR was defined as disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Up to Week 16
Reported as:
Number · percentage of participants
CBR With SD Duration of at Least 16 Weeks
percentage of participantsArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
CBR With SD Duration of at Least 16 Weeks40.625.029.0
Statistical analysis
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm B: Single-agent MLN0128 30 mg QW · Odds ratio (or): 0.47 · 95% CI 0.16 to 1.38Odds ratio and 95% CI was obtained using a stratified CMH model with prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category.
  • Arm A: Single-agent Everolimus 10 mg QD vs Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD · Odds ratio (or): 0.60 · 95% CI 0.20 to 1.80Odds ratio and 95% CI was obtained using a stratified CMH model with prior lines of therapy and the international metastatic renal cell carcinoma database consortium risk category.

Adverse events

Collected over All-cause mortality: From first dose of study drug through end of the study (up to 51 months); Serious and other (non-serious) AEs: From first dose of study drug through 30 days after the last dose of study drug (up to 31 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Single-agent Everolimus 10 mg QD16/32 (50%)19/32 (59.4%)32/32 (100%)
Arm B: Single-agent MLN0128 30 mg QW18/32 (56.3%)13/32 (40.6%)29/32 (90.6%)
Arm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD19/32 (59.4%)15/31 (48.4%)31/31 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
PneumoniaInfections and infestations3/320/320/31
AscitesGastrointestinal disorders0/320/322/31
AnaemiaBlood and lymphatic system disorders0/320/322/31
SepsisInfections and infestations2/321/320/31
AstheniaGeneral disorders0/322/321/31
Acute kidney injuryRenal and urinary disorders0/322/321/31
Metastatic renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/322/320/31
Septic shockInfections and infestations0/321/321/31
General physical health deteriorationGeneral disorders1/320/321/31
PyrexiaGeneral disorders1/320/321/31
Most frequent other events
Showing 10 of 79
Most frequent other events
EventArm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QD
NauseaGastrointestinal disorders7/3222/3217/31
AstheniaGeneral disorders19/3212/329/31
Decreased appetiteMetabolism and nutrition disorders15/3210/3211/31
VomitingGastrointestinal disorders7/3214/3213/31
DiarrhoeaGastrointestinal disorders13/328/3211/31
FatigueGeneral disorders10/326/3212/31
ConstipationGastrointestinal disorders9/3212/325/31
StomatitisGastrointestinal disorders12/326/323/31
PruritusSkin and subcutaneous tissue disorders3/3212/326/31
CoughRespiratory, thoracic and mediastinal disorders11/3210/323/31

Baseline characteristics

Full Analysis Set included all randomized participants.

Age, Continuous
Age, Continuous(years)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
Mean64.7 ± 11.4161.6 ± 8.9063.3 ± 9.0663.2 ± 9.83
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
Female610723
Male26222573
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
Hispanic or Latino0022
Not Hispanic or Latino28302785
Unknown or Not Reported4239
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
American Indian or Alaska Native0000
Asian1001
Native Hawaiian or Other Pacific Islander0000
Black or African American0011
White27292783
More than one race0000
Unknown or Not Reported43411
Region of Enrollment
Region of Enrollment(Participants)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
Czech Republic1124
France4228
Italy119424
Poland2215
Spain66719
United Kingdom44917
Canada2125
United States27514
Height
Height(cm)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
Mean170.23 ± 8.489171.16 ± 10.626172.01 ± 8.349171.13 ± 9.159
Weight
Weight(kg)Arm A: Single-agent Everolimus 10 mg QDArm B: Single-agent MLN0128 30 mg QWArm C: Combination of MLN0128 4 mg QD + MLN1117 200 mg QDTotal
Mean75.69 ± 12.44978.12 ± 15.47380.40 ± 17.89678.10 ± 15.419
08

Study locations

36 sites
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Florida Cancer Specialists-Broadway
    Venice, Florida 33916, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Hackensack University Medical Center PARTNER
    Hackensack, New Jersey 07601, United States
  • The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital
    Columbus, Ohio 43210, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • The Center for Cancer and Blood Disorders
    Weatherford, Texas 76086, United States
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • McMaster University
    Hamilton, Ontario L8N 4A6, Canada
  • Fakultni nemocnice u sv. Anny v Brne
    Brno, 656 91, Czechia
  • Fakultni nemocnice Olomouc
    Olomouc, 775 20, Czechia
  • Fakultni nemocnice v Motole
    Prague 5, 150 06, Czechia
  • Groupe Hospitalier Saint Andre - Hopital Saint Andre
    Bordeaux cedex, Aquitaine 33075, France
  • ICL-Alexis Vautrin, Departement dOncologie Medicale
    Vandoeuvre les Nancy Cedex, Meurthe Et Moselle 54511, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris cedex 13, Paris 75651, France
  • Institut de Cancerologie de l'Ouest Paul Papin
    Angers Cedex 9, PAYS DE LA Loire 49933, France
  • Clinique Victor Hugo - Centre Jean Bernard
    Le Mans Cedex 02, Sarthe 72015, France
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, 40138, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale
    Napoli, 80131, Italy
  • IOV - Istituto Oncologico Veneto IRCCS
    Padova, 35128, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Beskidzkie Centrum Onkologii im.Jana Pawla II
    Bielsko-Biala, 43-300, Poland
  • Instytut MSF, Ulica Pilota Stanislawa Wigury 19
    Lodz, 90-302, Poland
  • Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barcelona 08023, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • MD Anderson Cancer Centre
    Madrid, 28033, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Royal Devon and Exeter Hospital (Wonford)
    Exeter, Devon EX2 5DW, United Kingdom
  • Lancashire Teaching Hospitals NHS Foundation Trust
    Blackburn, England BB2 3HH, United Kingdom
  • Barts Hospital
    London, Greater London EC1M 6BQ, United Kingdom
  • The Christie
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Velindre Cancer Centre
    Cardiff, South Glamorgan CF14 2TL, United Kingdom
  • Royal Surrey County Hospital
    Guildford, Surrey GU2 7XX, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Feb 2020, 43 months.

Results were first posted in Feb 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2016
First posted
Mar 31, 2016
StartActual
Jun 30, 2016
Primary completionActual
Feb 3, 2020
CompletionActual
Oct 13, 2020
Results first posted
Feb 21, 2021
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02724020
Responsible party
Sponsor
First posted
Mar 31, 2016
Start date
Jun 30, 2016
Primary completion
Feb 3, 2020
Completion
Oct 13, 2020
Results posted
Feb 21, 2021
Last update
Nov 19, 2021

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sapanisertib · Serabelisib

Start the discussion